

PATIENT INFORMATION

Date:	Patient Name:	Last 4 SSN	DOB:
Address:	City:	ST:	Zip:
Primary Phone:		Work Phone:	
Gender: M F	Weight lbs/kg:	Height:	Allergies:
Primary Insurance:		Secondary Insurance:	
Member#:	Group#:	Member#:	Group#:

Diagnosis: _____

Documentation needed: Insurance cards Most recent clinical including H&P Labs Diagnostic testing results

Medication	Order
Cimzia – Subcutaneous or IV (suite only)	<input type="checkbox"/> Initial: 400 mg week 0, week 2, week 4, then maintenance <input type="checkbox"/> Maintenance: 400 mg every 2 weeks <input type="checkbox"/> Other: <input type="checkbox"/> Sub-Q <input type="checkbox"/> IV (Suite Only)
Dupixent - Subcutaneous	<input type="checkbox"/> 300 mg sub-Q every week <input type="checkbox"/> Other:
Entyvio - IV	<input type="checkbox"/> Initial: 300 mg week 0, week 2, week 6, then maintenance <input type="checkbox"/> Maintenance: Every 8 weeks <input type="checkbox"/> Other:
Humira - Subcutaneous	<input type="checkbox"/> Induction: 160 mg sub-Q day 1, 80 mg day 15 <input type="checkbox"/> Maintenance: 40 mg sub-Q every other week <input type="checkbox"/> Other:
Infliximab - IV <input type="checkbox"/> Remicade <input type="checkbox"/> Inflectra <input type="checkbox"/> Renflexis	Freq: <input type="checkbox"/> Initial: week 0, week 2, week 6, then maintenance <input type="checkbox"/> Maintenance: Every 8 weeks <input type="checkbox"/> Every ____ weeks <input type="checkbox"/> 5 mg/kg <input type="checkbox"/> 10mg/kg <input type="checkbox"/> ____ mg/kg <input type="checkbox"/> ____ mg
Simponi - Subcutaneous	<input type="checkbox"/> Initial: 200 mg sub-Q week 0, 100 mg week 2, then maintenance <input type="checkbox"/> Maintenance: 100 mg sub-Q every 4 weeks <input type="checkbox"/> Other:
Simponi Aria - IV	<input type="checkbox"/> Initial: 2mg/kg week 0 and 4, then maintenance <input type="checkbox"/> Other: <input type="checkbox"/> Maintenance: Every 8 weeks <input type="checkbox"/> Other:
Skyrizi – Subcutaneous/IV (initial only)	<input type="checkbox"/> Initial *IV*: 600 mg week 0, week 4, and week 8, then subcutaneous maintenance <input type="checkbox"/> Maintenance *Subcutaneous*: <input type="checkbox"/> 180 mg <input type="checkbox"/> 360 mg week 12 and every 8 weeks thereafter <input type="checkbox"/> Other:
Stelara - Subcutaneous	<input type="checkbox"/> 90 mg <input type="checkbox"/> Every 8 weeks <input type="checkbox"/> Every ____ weeks
Stelara - IV (Suite Only)	<input type="checkbox"/> 260 mg <input type="checkbox"/> 390 mg <input type="checkbox"/> 520 mg One time initial dose, then maintenance via subcutaneous injections

Tysabri – IV (Suite Only) IV	<input type="checkbox"/> 300 mg Freq: Every 4 weeks
Xeljanz - Oral	<input type="checkbox"/> Induction: <input type="checkbox"/> 10 mg PO twice daily <input type="checkbox"/> 22 mg XR PO once daily For _____ weeks <input type="checkbox"/> Maintenance: <input type="checkbox"/> 5 mg PO twice daily <input type="checkbox"/> 11 mg XR PO once daily <input type="checkbox"/> Other:

Nursing

- Establish and/or maintain access device as needed for dose administration
- Administer by ordered route
- Obtain vital signs prior to, throughout as directed and at completion of infusion
- If reaction occurs follow procedure reaction management

PROVIDER INFORMATION

By signing I certify that the use of the indicated treatment is medically necessary and I will be supervising the patient's treatment. Axiva Health Solutions, Inc., has my permission to contact the patient's health plan to obtain authorizations necessary to enable it to receive payment for services.

Physician Name:	NPI:	DEA:	License:
Address:	City:	ST:	Zip:
Phone:	Fax:	Office Contact:	

 Physician Signature Required – Substitution Permitted Date ◆ Physician Signature Required – Dispense as Written Date